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M itochondrial complex I (NADH:ubiquinone oxidor-eductase)1 is central to oxidative phosphorylation inmammalian cells. It captures the free energy released
from reduction of ubiquinone by NADH to pump protons across
the inner mitochondrial membrane, support the proton-motive
force and power ATP synthesis. As an essential respiratory
enzyme, and an important contributor to cellular oxidative stress,
complex I dysfunctions resulting from mutations in its subunits
and assembly factors cause a diverse set of inherited neuromus-
cular and metabolic diseases2.
Mammalian complex I comprises 45 subunits: fourteen “core”
subunits, which are conserved from bacteria to humans and
sufficient for catalysis, and 31 “supernumerary” subunits, which
are required for assembly, stability, regulation, or fulfil indepen-
dent metabolic roles1,3. Understanding of the structure of
mammalian complex I has leapt forward in recent years due to
the advent of high-resolution single particle electron cryo-
microscopy (cryoEM). The structure of complex I from mouse
heart mitochondria was described recently at 3.3 Å resolution4
and that of the yeast Yarrowia lipolytica at 3.2 Å5. The structures
illustrate how, as shown previously in the enzyme from Thermus
thermophilus6, electrons enter from NADH oxidation, at the top
of the hydrophilic domain, and are transferred towards
the membrane along a chain of iron-sulphur (FeS) clusters.
The terminal cluster, a [4Fe-4S] cluster known as N2, then
donates the electrons to ubiquinone-10 (Q10). The hydrophobic
Q10 enters the enzyme from the mitochondrial inner membrane
through a long binding channel, elevating its redox active head-
group out of the membrane plane to within electron-transfer
distance of N2. Although ubiquinone binding, reduction, and
dissociation are now beginning to be defined by structural and
functional data5,7,8, the mechanism that couples the redox reac-
tion to proton translocation remains poorly understood.
The quinone binding tunnel in complex I is long and hetero-
geneous; the top and bottom sections are hydrophobic, while the
central section is surrounded by many charged residues6,8. The
charged region may be important in linking redox catalysis to
proton translocation, because it sits at the start of a chain of
charged residues that leads into the membrane plane4,6,9, and
involves the loops from membrane-bound subunits ND1 and
ND3 that may move during catalysis10. The structures of the
mammalian enzyme in both its active and deactive states depict
how these loops become disordered when complex I converts
from its ready-to-catalyse “active” state to its “deactive” state. The
deactive state is a pronounced resting state that forms sponta-
neously at physiological temperatures in the absence of turnover,
and requires reactivation by both NADH and ubiquinone in
order to re-enter the catalytic cycle3,4,11.
The large, heterogeneous and conformationally-labile nature of
the ubiquinone binding site may explain, why such a wide variety
of compounds with little resemblance to the substrate inhibit
complex I12–14. However, only limited structural information is
available on their bound states. Density for piericidin was shown
pictorially in the structure of Thermus thermophilus complex I6,
but neither the model nor data were made available, precluding
evaluation of the information. The inhibitor 2-decyl-4-
quinazolinyl amine has been observed with its headgroup part
way up the ubiquinone binding channel of complex I from Y.
lipolytica10. For several families of inhibitor, including pier-
icidin12,15 extensive structure-function studies have been under-
taken, but the information is difficult to interpret without detailed
knowledge of the inhibitor-binding mode. No structures of
inhibitors bound to the mammalian enzyme have been presented,
despite their inherent biomedical interest16,17, and that inhibitor-
bound structures present unrivalled opportunities to access dif-
ferent mechanistically-relevant enzyme states.
Piericidin is a natural insecticide that was first isolated in the
1960s from the spore forming bacterium Streptomyces mobar-
aensis18, and has now been synthesised chemically19. It is a
tight-binding complex I inhibitor20 that resembles a short chain
ubiquinone (Q3). The headgroup resembles the ubiquinone
headgroup (see Fig. 1), except one of the two carbonyls (reduced
to hydroxyls in ubiquinol) is replaced by a 4-pyridone nitrogen.
The hydrophobic tail contains an initial isoprenoid followed by
two isoprenoid-like groups, with a hydroxyl group close to its
end. Piericidin has been described to compete for the same or
overlapping binding sites as the inhibitors rotenone and DQA21,
and to display partially-competitive inhibition with the substrate

















































Fig. 1 Piericidin bound in the structure of mammalian complex I. a The
piericidin molecule is located at the interface between the redox (blue) and
proton-transfer (green) domains; supernumerary subunits in grey. Charged
residues in the proton-transfer domain are marked in purple. M matrix,
IMM inner mitochondrial membrane, IMS intermembrane space.
b Piericidin (left) and a docked-in Q10 (right) in the proposed ubiquinone-
binding cavity, leading from Tyr108 and His59 to outside the protein. The
internal surface of the cavity was identified using PyMol-1.8.4.0. NDUFS7
helix 4 (residues 104–117) has been removed for clarity. c The structures of
piericidin and Q10 with differences highlighted in red.
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(DQ)23. It inhibits both the forward NADH:ubiquinone oxidor-
eductase reaction, and reverse electron transfer (succinate-driven
reduction of NAD+ in submitochondrial particles) with equiva-
lent efficacy24. 14C-labelled piericidin studies describe two non-
cooperative binding sites for piericidin for complex I in its native
lipid environment, but only one in the delipidated enzyme24,25.
Here, we have used the canonical complex I inhibitor piericidin
A1 (referred to hereon as piericidin for simplicity) to determine
the structure of complex I with a ubiquinone-analogue inhibitor
bound in its active site. We combine structural, kinetic, spectro-
scopic, and computational analyses to elucidate the inhibitor-
binding mode and the relationships between piericidin and ubi-
quinone binding, and find evidence for a distal ubiquinone/
inhibitor binding site in the central region of the quinone-binding
channel. Our piericidin-bound structure is the highest resolution
structure of mammalian complex I in an active-like state so far
reported, and it reveals information about the mechanisms of
inhibition and ubiquinone reduction.
Results
Determination of the structure of piericidin-bound complex I.
Piericidin-inhibited complex I was prepared by adding piericidin
to the enzyme during turnover with NADH and DQ to ensure
exposure of the inhibitor-binding state. Residual substrates and
inhibitor were then removed to ensure any inhibitor present was
specifically bound. The sample of mouse complex I analysed by
cryoEM was 89 ± 3% inhibited by comparison with a control
sample prepared identically but without inhibitor. The complex
was frozen onto PEGylated gold grids and two datasets (Sup-
plementary Table 1) with similar pixel sizes, and numbers of
micrographs were collected on FEI Titan Krios microscopes,
using either a Gatan Quantum K2 Summit detector with energy
filter (piericidin-K2) or an FEI Falcon III detector in counting
mode (piericidin-FIII). Both datasets were processed by RELION-
3.0 to 3.0 Å resolution (Supplementary Figs. 1, 2, 3 and Supple-
mentary Table 1). Once sharpened, the two maps are essentially
indistinguishable: the piericidin-K2 map was used unless other-
wise stated. The dataset for the active state of mouse complex I
(referred to as active complex I) described previously4, which
reached 3.3 Å resolution with RELION-2.1, was then reprocessed
with RELION-3.0 to 3.1 Å (Supplementary Figs. 2, 3 and Sup-
plementary Table 1). The resolutions achieved enabled confident
modelling of 97% of the 8430 residues of both the piericidin-
bound and active enzymes (Supplementary Table 2).
Piericidin binding at the top of the ubiquinone-binding
channel. Density for a bound piericidin was readily identified
at the top of the ubiquinone-binding cavity, where the ubiqui-
none ring and first three isoprenoids of ubiquinone-10 are
expected to bind (Figs. 1 and 2a, b). Overall, the piericidin-bound
maps and model match those for active complex I very closely






































































Fig. 2 Cryo-EM densities for the piericidin molecule, and interactions between the protein and the bound piericidin. a, b Cryo-EM densities for the
piericidin-containing region (black mesh, top) and the difference between the piericidin-free protein model and the piericidin-bound density (teal mesh,
calculating using the phenix.real_space_diff_map command) for a the piericidin-K2 and b the piericidin-FIII datasets. A putative water molecule can be
observed in the lower left of each panel (marked by an asterisk). Densities rendered in UCSF Chimera at thresholds of a 0.0163, 6.07 and b 0.0294 and
5.82. c Residues around the piericidin; proposed hydrogen bonds marked in black, other distances in grey. dMovement of the NDUFS2 β1-β2 loop between
the active (magenta) and piericidin-bound (wheat) models. e Interactions of NDUFS2-His59 with the piericidin headgroup and Asp160, depending on the
rotation of the His ring; refined structure with interaction with piericidin 2′ methoxy, and ring flipped to form interaction with Asp160. All distances in Å.
Subunits NDUFS2 and NDUFS7 are abbreviated as FS2 and FS7, respectively.
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in UCSF Chimera and all atom RMSD= 0.6 Å, relative to 2.7 Å
for the deactive state (PDB:6G72)) and exhibit all the hallmarks of
it: the extended interface between NDUFA5 and NDUFA10 that
defines the arrangement of the hydrophilic and membrane
domains4; clear densities for the mobile loops in NDUFS2, ND3,
and ND13,4,11; and α-helical structure throughout ND6-TMH34.
Two short stretches of NDUFS7 (residues 58–60 and 86–92,
where R91 is known to be hydroxylated)26 also match the active
state. Therefore, we observe piericidin bound to the active state of
complex I, in which the ubiquinone-binding site is fully config-
ured and ready for catalysis.
The piericidin headgroup binds adjacent to NDUFS2 His59
and Tyr108, the two proposed ligands of the ubiquinone
headgroup (Fig. 2c). Its ring carbonyl accepts a hydrogen bond
from the Tyr108 hydroxyl (O–O distance 3.4 Å), consistent with
the keto form of the piericidin headgroup (rather than the
tautomeric enol form with an aromatic ring, a deprotonated
pyridone-N and a hydroxyl). Because piericidin lacks a second
carbonyl it cannot form a second ubiquinone-like hydrogen
bond to His59. Instead, His59 Nδ1 forms a hydrogen bond (N–O
distance 3.2 Å) with the piericidin 2′ methoxy (Fig. 2c).
Alternatively, a good fit to the density can be obtained from
flipping the imidazole ring to form a hydrogen bond (albeit with
poor geometry) between His59 Nε2 and Asp160 (N–O distance
2.4 Å) (Fig. 2e). To accommodate the piericidin, His59 has shifted
by ~2.5 Å (Fig. 2d); this is the only difference that could be
identified between the piericidin-bound and active structures.
Additional residues around the piericidin may further stabilise
it. In particular, NDUFS7-Met70 and NDUFS2-Met152 point
towards one face of the ring (Fig. 2c) and the sidechain of
NDUFS2-Thr156 is modelled 3.5 Å from the 2′ piericidin
methoxy, and could be rotated to bring its hydroxyl group into
a hydrogen-bonding configuration (but compromising the fit to
the density). Interestingly, weak densities observed between the
Thr156 hydroxy, the piericidin methoxy groups, and NDUFS2
Lys371 may arise from bound water molecules and reflect a wider
hydrogen-bonded network for ubiquinone protonation/reduction
(see below). However, we are not sufficiently confident to model
water networks at the current resolution. The piericidin
isoprenoid-like tail tracks along the proposed ubiquinone-
binding channel, overlapping the predicted positions of iso-
prenoids one to three (Figs. 1, 2) and surrounded by a series of
hydrophobic sidechains (Fig. 2c), including NDUFS7 Phe86 in a
π–π interaction and NDUFS2-Phe167 and Phe168 framing the
final isoprenoid-like unit. The sidechains of NDUFS7-Thr59 and
ND1-Glu204 are near to the hydroxy group on the piericidin
chain, but too far to form hydrogen bonds. Glu204 is on the
TMH5-6 loop of ND1 at the start of the “E-channel” that
connects the ubiquinone-binding site to charged residues in the
membrane domain4,6.
Molecular dynamics (MD) of piericidin in the substrate
binding pocket. To probe the pieridicin-binding mode further,
we performed classical MD simulations, starting from the
piericidin-bound cryoEM model. The piericidin was modelled
into the density, or docked in using MD flexible fitting (MDFF)27
with the density as a biasing potential. During the MD simula-
tions (Fig. 3 and Supplementary Fig. 4), the NDUFS2 Tyr108-OH
forms a stable hydrogen bond with the piericidin 4′ carbonyl,
consistent with the cryoEM model, but at a slightly shorter dis-
tance of ~2.9 Å (Fig. 3c). NDUFS2 His59, modelled as the doubly-
protonated imidazolium (HisH+) samples a hydrogen-bonded
conformation with the piericidin 2′ methoxy, but prefers an
alternative conformation, resembling that obtained by flipping
the His59 ring as in Fig. 2e (right) and stabilised by van der Waals
interactions. The histidine further forms an ion-pair interaction
with Asp160 (Fig. 3c). Interestingly, simulations with a neutral
histidine (Nδ-protonated only) resulted in His59 and the
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Fig. 3 Molecular dynamics simulations of piericidin in complex I. a Snapshots from the MD simulations of piericidin in van der Waals (VdW)-stabilised
and hydrogen-bonded conformations. Hydrogen bonds are indicated by dotted lines. b Interaction energies between piericidin and selected surrounding
residues (total, van der Waals, and electrostatic contributions in kcal mol−1). Green, residues in NDUFS2; red, residues in NDUFS7. The boxes extend from
the 25th to the 75th percentile, the middle line represents the median. The whiskers show the range of the data from the 10th to 90th percentile (n= 1500,
snapshots calculated every 40 ps). c Distance distributions (simulations A1–A4, Supplementary Table 4) and time traces of distances (simulation A1)
between piericidin (P) and key residues. Left: piericidin 4′ carbonyl oxygen to Tyr108 hydroxyl oxygen. Middle: piericidin 2′ methoxy oxygen to His59
(centre of mass of Nδ/Cε/Nε). Right: His59 (centre-of-mass of Nδ/Cε/Nε) to Asp160 (centre-of-mass of carboxylic group). Experimental distances
(Fig. 2c) for the refined structure (dark grey) and ring-flipped model (light grey) are shown as dotted lines. See Supplementary Fig. 4 for further time traces
from individual simulations, and distances to Thr156. d The two modelled piericidin molecules with the experimental cryo-EM density (PyMol-2.2.3 density
level 4.0, carve radius= 1.8) and surrounding residues. e Distance distributions of piericidin in the substrate cavity obtained from classical (left, simulation
A1–A5, 220 ns total) and coarse-grained MD simulations (right, simulation C1–C10, 100 µs total). Distances are between the centre of masses of the
Tyr108 and piericidin rings.
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NDUFS2 β1–β2 loop moving away from the piericidin and
Asp160, suggesting histidine protonation is required for stable
piericidin binding. Hybrid quantum/classical (QM/MM) simu-
lations, in which the binding site was modelled using density
functional theory (DFT) polarised by a classical model for the
surrounding protein, also revealed the hydrogen-bonded and van
der Waals binding poses. In addition, at the expense of atomistic
detail but with enhanced statistical sampling, coarse-grained (CG)
MD simulations support the piericidin remaining stable in the
binding pocket for several tens of microseconds. Finally, energy
decomposition analyses based on the MD simulations (Fig. 3b
and Supplementary Fig. 5) suggest that His59, Tyr108, and
Asp160, as well as NDUFS2 Val424 and Phe425, which move
closer to the piericidin ring in some of the simulations, make
strong contributions to the interaction energy. Although
NDUFS2 Thr156 samples transient hydrogen-bonded interac-
tions with the 2′ methoxy (Fig. 3a and Supplementary Fig. 4d) it
contributes only moderately to the interaction energy, along with
NDUFS7 Met70 and NDUFS2 Met152 (Supplementary Fig. 5).
Commensurate with the additional densities observed in the
cryoEM analyses, water clustering analyses (see Supplementary
Fig. 5b and see “Methods” section) suggest that this region could
form a stable water binding site, stabilised by the nearby con-
served residues NDUFS2 Asp107 and Asp422.
The environment of cluster N2. During the inhibitor-binding
incubation, complex I was exposed to NADH to induce turnover
and ensure exposure of the inhibitor-binding site. Inhibitor
binding prevents reoxidation by DQ, so to determine if the
enzyme was prepared in the reduced state, the same protocol was
used to prepare a larger amount of the piericidin-bound bovine
complex (inhibited by 72 ± 6%) for EPR analyses. With no extra
NADH added to reduce the sample, the signal from reduced FeS
cluster N2 was clearly observed in the inhibited sample (Fig. 4a).
It was also observed in the turnover control (that was prepared
identically but not exposed to piericidin), but not in the matching
“nonturnover” control to which NADH had not been added
(Fig. 4b). No signals from any other reduced clusters were
observed. The reduction of only N2 is consistent with the rela-
tively high reduction potential of this cluster in the mammalian
complex28,29, disfavouring electrons transferring from N2 back to
the low-potential flavin where they may slowly escape to O230.
The samples were subsequently thawed and NADH added to
reduce N2 completely, showing that N2 was 78% reduced in the
inhibited sample, 44% reduced in the turnover control, and fully
oxidised in the nonturnover control. Therefore, we infer that
cluster N2 was predominantly reduced in the piericidin-bound
sample used for cryoEM, although the small scale of the cryoEM
preparation precludes direct measurement. Strikingly, Fig. 4c
shows that the environments of N2 in the piericidin-bound (N2-
reduced) and active (N2-oxidised) states of mouse complex I are
indistinguishable. Even NDUFS2-His190, which becomes proto-
nated at pH < 7.4 when N2 is reduced29,31 and has a well-defined
density in both maps, does not move. Furthermore, the lack of
any substantial structural change “downstream” of N2 in the
proton pumping modules is consistent with our previous con-
clusion29 that N2 redox cycling is not the coupling reaction that
initiates proton translocation.
Kinetic evidence for the binding of two inhibitor molecules.
Inhibition of complex I by piericidin was studied in proteolipo-
somes reconstituted with complex I, Q10, and an excess of the
cyanide-insensitive alternative oxidase (AOX) to recycle the
ubiquinol back to ubiquinone32,33. Proteoliposomes were pre-
pared with varying ubiquinone concentrations to span the KM
curve, and characterised by their phospholipid content (hydro-
phobic phase volume), ubiquinone concentration, and complex I
concentration and orientation. Complex I inhibition was then
investigated by titrating the rate of NADH oxidation with pier-
icidin. Figure 5 shows that the data can be modelled by a series of
Michaelis–Menten curves for their Q10 dependence, and a series
of IC50 curves for their piericidin dependence. Interestingly, both
the apparent KM and Vmax values decrease with increasing pier-
icidin concentration, contrary to the behaviour expected for a
competitive inhibitor (increasing KM and constant Vmax)—
although the piericidin is clearly observed in the binding site for
the ubiquinone headgroup in the cryoEM map. Different models
were therefore tested as follows. The complex I, ubiquinone-10,
and piericidin concentrations were defined relative to the mem-
brane volume, and the ratio of membrane to aqueous piericidin
were set by its partition constant (log10P= 4.73). Reoxidation of






























Turnover control as prepared
Turnover control + 10 mM NADH
Non-turnover control
c
Fig. 4 Cluster N2 is reduced in the piericidin-bound enzyme but its
surrounding structure does not change. a EPR spectra showing reduced
clusters in the piericidin-treated sample as prepared (black) and following
addition of 10 mM NADH (grey). b EPR spectra showing reduced clusters in
the piericidin-free control samples: the turnover control as prepared (black)
and following addition of 10mM NADH (grey) and the nonturnover control
as prepared (red). EPR conditions: 9.5 GHz (X-band), temperature 20 K,
microwave power 2.0 mW, modulation frequency 100 kHz, modulation
amplitude 0.7 mT. c Key residues around N2 in the piericidin-bound (teal)
and active (wheat) states. Distances are in Å. NDUFS2-Tyr108, the ligand
to the piericidin headgroup, is shown for reference.
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10 was not considered. Importantly, piericidin is a tight-binding
inhibitor, and the pool of ubiquinone/ubiquinol is small, so
depletion of their free concentrations upon binding were con-
sidered. Although this precluded simple analytical solution of the
rate equations and required kinetic rates to be calculated
numerically, the numerical approach also enabled us to test
essentially any reasonable model without having to make sim-
plifying assumptions, such as about the identity of the rate
determining step in complex I catalysis.
Figure 5 confirms that the simplest competitive inhibition
model does not account for the data. The sum of the squared-
residuals (SSR) for the overall fit (taking into account every data
point) is high (Supplementary Table 3) and the observed trends
in the apparent values for KM, Vmax, IC50, and Hill slope are not
replicated. However, by introducing a second binding site to the
model, the fit improves substantially: the SSR decreases 7-fold
and trends in KM, Vmax, and IC50 are predicted well. Early work
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KM,app Vmax,app IC50,app Hill Slope
1-site
2-site
Fig. 5 Competitive models for piericidin inhibition of complex I in proteoliposomes. a One-site competitive inhibition mechanism. b Two-site competitive
inhibition mechanism. In both cases, rapid reoxidation of ubiquinol by AOX (k4) prevents appreciable levels accumulating. Experimentally-measured rates
(average ± standard deviation, n= 3) are shown in KM and IC50 plots, alongside the best-fit predictions from the models (see Supplementary Table 3 for
parameters). c Plots of trends in KM,app, Vmax,app, IC50 and Hill slope produced by fitting KM and IC50 curves to the experimental data (black points, error
bars are 95% confidence intervals) and to the output data from the models. The SSR values are 201 and 46.7 for a and b, respectively.
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stoichiometry of 224, and the Hill slopes of the IC50 curves
determined here are around 2, suggestive of cooperative binding.
Intriguingly, and consistent with the cooperativity, the best-fit KI
values (where KI is the dissociation constant for the inhibitor)
suggest the second inhibitor binds substantially more tightly than
the first, with a broad minimum in SSR at KI2/KI1= 10−5 to 10−1,
and the minimum point at 10−4, with a 10,000× tighter binding
of the second piericidin than the first (see below). Further analysis
(Supplementary Table 3) showed that both a single inhibitor
binding competitively to the ubiquinol-binding state, and a
simple mixed (both competitive and uncompetitive) binding
scheme also resulted in poor fits. A two-site uncompetitive
binding model, where piericidin binds to the enzyme-substrate
complex, was also able to explain the data satisfactorily, but this
kinetic model is not supported by the structural data. Therefore,
the kinetic data strongly support the two-site competitive
inhibition model, implying that more than one piericidin enters
the ubiquinone-binding channel.
Evaluation of densities in the distal section of the ubiquinone-
binding channel. Broken, noisy densities are observed in the
“distal” section of the ubiquinone-binding channel in both the
piericidin-K2 and piericidin-FIII maps (Fig. 2a, b). However, they
are insufficiently resolved for identification—and similar densities
are also observed in the active mouse map4. To probe whether an
additional piericidin would fit the extra densities in the piericidin-
K2 map, we performed MD simulations with a second piericidin
added. The fitted distal molecule adopts positions that adequately
explain the density features observed (albeit with insufficient
confidence for inclusion in the cryoEM model), and a hydrogen-
bonding interaction was observed to form intermittently between
the C10-hydroxyl on the proximal molecule and the 4′ carbonyl
on the distal molecule (Fig. 3d). As expected for its location at the
position of isoprenoid 4, the headgroup of the distal molecule is
also surrounded by a number of charged residues8. The charged
region, followed by a more hydrophobic region toward the
channel entrance, may provide a favourable environment for a
range of amphipathic species, and it also corresponds (Fig. 3e) to
a recently proposed ubiquinone-binding subsite (site 2) identified
in simulations on bacterial complex I34. However, the distal
piericidin does not adopt a single, well-defined binding pose, and
its fluctuations in the MD simulations, together with the unclear
density, are better explained by a broad substrate recognition
region, rather than a unique, well-defined distal site. The broad
recognition region may lead to an entropic stabilisation for the set
of subsites to provide a higher affinity for the site as a whole,
whereas the interaction between the two piericidins may con-
tribute to the cooperativity, explaining the tighter apparent
binding of the second piericidin relative to the first.
Notably, early work to determine the number of piericidins
bound to complex I showed there are two nonidentical specific
binding sites per membrane-bound enzyme, but that this
decreases to one in the delipidated enzyme24,25. Loss of high
affinity piericidin binding in the detergent-solubilised enzyme,
relative to in the membrane, has also been described22. Our data
are consistent with two piericidins binding in our membrane-
bound enzyme assay, and with lower occupancy of the distal site
in the detergent-solubilised, structurally-characterised enzyme.
Specific phospholipids are known to be essential for complex I
activity35 and their loss and/or the presence of detergent may
destabilise the second piericidin, and affect the properties of the
distal section of the ubiquinone-binding channel. Although our
results thus present an example of how the structurally-
characterised detergent-solubilized protein differs from the
membrane-bound enzyme, our interpretation is consistent with
an important role for phospholipids, and cardiolipin in particular,
in complex I catalysis35,36.
Discussion
Our structures show that piericidin binds at the top of the
ubiquinone-binding site between NDUFS2-Tyr108 and NDUFS2-
His59, two highly conserved residues long known to be critical for
catalysis37,38. Tyr108 hydrogen bonds with the piericidin 4′ car-
bonyl, and our MD simulations suggest it makes a substantial
contribution to the binding energy (Fig. 3b and Supplementary
Fig. 5). Intriguingly, in the complex I genes present in
S. mobaraensis, from which piericidin was isolated, a tryptophan
replaces Tyr10839. There are currently no structures available for
ubiquinone bound to complex I, but simulations on the T. ther-
mophilus enzyme40 support an analogous hydrogen bond
between Tyr108 and the ubiquinone 4′ carbonyl, poised to pro-
tonate the nascent quinol. In the yeast Y. lipolytica, all variants of
the Tyr (Y144) rendered the enzyme essentially unable to reduce
Q9, while Q1 and Q2 supported near wild-type Vmax values but
with substantially increased KM values38. IC50 values for the
inhibitor 2-decyl-4-quinazolinyl amine (DQA), measured with
Q1, were similarly increased in Tyr mutants37—despite structural
data showing DQA bound further along the binding channel10.
Data on the role of His59 in ubiquinone binding and reduction
is less conclusive. In piericidin, the 1′ carbonyl is replaced by a
pyridone nitrogen hydrogen bond donor (N–H), so His59 must
interact differently with piericidin than ubiquinone. Here, the His
is observed to hydrogen bond to the 2′ piericidin methoxy.
However, our MD simulations suggest piericidin samples two
different binding poses, one stabilised by hydrogen bonding and
one by van der Waals interactions. Confusingly, while the Ala,
Met, or Arg variants of His59 (His95) in Y. lipolytica abolished
catalysis with no deleterious effects on assembly38, the analogous
NuoD-His224 to Arg variant in E. coli gave an enzyme with near
wild-type activity with all quinones tested, and near wild-type
inhibitor-binding characteristics41. The exact interaction mode(s)
of His59 with the ubiquinone headgroup and its role in catalysis
thus remain unconfirmed.
Variants of NDUFS2-Thr156, NDUFS7-Met70, and NDUFS2-
Met152, identified here as relevant to binding, have also been
studied in Y. lipolytica. Rotenone and DQA inhibit more weakly
in Y. lipolytica than in the mammalian enzyme42. Mutating Y.
lipolytica Ser192, homologous to mouse Thr156, to Thr increased
the affinities for both rotenone and DQA, whereas mutations to
Ile, Arg, and Tyr were all detrimental to activity7. Variants of
Met70 (Yl Met91) showed increased KM values with Q1 and Q2,
with Vmax hardly affected, and resistance to DQA and rotenone43.
Similarly, variants of Met152 (Yl Met188) exhibited varying
amounts of activity with all quinones42. Finally, in Rhodobacter
capsulatus residues on the C-terminal helix of NDUFS2, parti-
cularly Val424 (Rc Val407) were found to affect piericidin bind-
ing44. Val424 is close to the 3′ methoxy group on the piericidin
headgroup, and is also identified in our energy decomposition
analysis (Supplementary Fig. 5).
Our data demonstrate that piericidin competes with ubiqui-
none for its binding site, and that piericidin binds to an active-like
state of mammalian complex I, with all elements of the
ubiquinone-binding site defined in the density. However, strictly
speaking, the structurally-characterised active state is an off-
pathway state with oxidised FeS clusters, because during catalysis
NADH oxidation outpaces ubiquinone reduction and cluster N2
is reduced. In contrast, our piericidin-bound structure contains a
reduced cluster N2, which does not lead to observable structural
changes. Charge delocalisation over the cluster core to minimise
reorganisation and facilitate rapid electron transfer, is a feature of
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3Fe-4S and 4Fe-4S cluster chemistry. For example, no substantial
changes upon reduction were detected in high resolution struc-
tures of the 7Fe ferredoxin I from Azotobacter vinelandii45. In
contrast, the NADH-bound, reduced structure of the hydrophilic
domain of complex I from T. thermophilus was documented to
show subtle movements in several helices at the hydrophilic/
membrane domain interface46. Corresponding movements are
not observed here suggesting they were not representative of the
intact enzyme. Furthermore, our density shows no disconnection
of either of the tandem cysteine residues that coordinate cluster
N2 (Fig. 4b), as described for reduced N2 in the T. thermophilus
hydrophilic arm, in which N2 is more highly solvent exposed46.
Our data indicate that two piericidins can be accommodated in
the ubiquinone binding channel in the membrane bound com-
plex, with the distal molecule occupying a site that broadly
resembles one of the additional binding sites for ubiquinone
predicted by simulations on the structure of T. thermophilus
complex I34. First, these sites may represent “staging posts” for
the transit of quinone/quinol along the long channel, where the
substrate pauses due to favourable interactions with its environ-
ment. This staging post concept may help to explain the relatively
low Vmax values of Q1 and Q28, since their small size renders
them susceptible to becoming trapped at these local energy
minima, and as multiple molecules may impede the progress of
each other. High concentrations of Q2, in particular, have been
reported to inhibit catalysis12. The same principles8 may help to
explain why piericidin (which has an alkyl chain length similar to
Q3) is so tight binding. The distal site sits within a network of
charged residues around the central region of the ubiquinone-
binding channel, connected to the E-channel, a series of gluta-
mate residues leading down into the membrane plane. It may
therefore be functionally relevant in the (as-yet unknown)
mechanism by which ubiquinone binding and reduction is cou-
pled to proton translocation.
Methods
Preparation of mouse complex I inhibited by piericidin for cryoEM. Piericidin-
inhibited mouse complex I was prepared by adapting the method of Agip and
coworkers for mouse complex I4. Six-week old C57BL/6 female mice were sacri-
ficed by cervical dislocation in accordance with the UK Animals (Scientific Pro-
cedures) Act, 1986 (PPL: 70/7538, approved by the local ethics committees of the
MRC Laboratory of Molecular Biology and the University of Cambridge and by the
UK Home Office) and the University of Cambridge Animal Welfare Policy. Hearts
were excised, immersed in ice-cold solution containing 10 mM Tris-HCl (pH 7.4 at
4 °C), 75 mM sucrose, 225 mM sorbitol, 1 mM EGTA and 0.1% (w/v) fatty acid-
free bovine serum albumin (Sigma-Aldrich), then cut into 1-mm pieces and
washed. The tissue was homogenised (10 mL buffer per gram tissue) by seven to
ten strokes of a Potter–Elvehjem homogeniser fitted with a Teflon pestle at ~1000 r.
p.m then the homogenate was centrifuged (1000 × g, 5 min), and the supernatant
recentrifuged (9000 × g, 10 min) to collect the crude mitochondria. The mito-
chondria were washed several times by resuspension and centrifugation and then
collected by centrifugation at 15,000 × g for 2 min, resuspended in 20 mM Tris-HCl
(pH 7.4 at 4 °C), 1 mM EDTA and 10% (v/v) glycerol to 10–20 mg protein mL−1
and frozen for storage. After thawing they were diluted to 5 mg protein mL−1, then
ruptured by three 5 s bursts of sonication (with 30 s intervals on ice) using a Q700
Sonicator (Qsonica) at 65% amplitude setting and the membranes were collected
by centrifugation (75,000 × g, 1 h), resuspended to 5 mg protein mL−1 and frozen
for storage.
Starting from 16mg membrane protein, the membranes were solubilized by
addition of 1% n-dodecyl β-D-maltoside (DDM, Glycon), stirred for 30 min on ice,
and centrifuged (48,000×g, 30 min). The supernatant was loaded onto a 1 mL Hi-
Trap Q HP anion exchange column (GE Healthcare) pre-equilibrated with buffer A
(20 mM Tris-HCl (pH 7.14 at 20 °C), 1 mM EDTA, 0.1% DDM, 10% (v/v) ethylene
glycol, 0.005% asolectin (Avanti) and 0.005% CHAPS (Calbiochem)). The column
was washed at 0.3 mLmin−1 with buffer A for 2 min, then with 20% buffer B
(buffer A+ 1M NaCl) for 7 min, and then complex I was eluted in 35% buffer B
for 10 min4. Complex I-containing fractions were pooled and concentrated to 100
μL using a 50 kDa MWCO spin column (Sartorius) and the following were then
added: 200 μM NADH, 6 μM decylubiquinone (DQ), 0.15% asolectin (20% soy PC,
Avanti) and 0.15% CHAPS (Calbiochem) to drive complex I catalysis; 150 μg mL−1
alcohol dehydrogenase from Saccharomyces cerevisiae (Sigma) and 1% ethanol to
regenerate the NADH from NAD+; 100 μg mL−1 alternative oxidase from
Trypanosoma brucei brucei (AOX8) to regenerate the ubiquinone from ubiquinol;
10 KUmL−1 catalase from Corynebacterium glutamicum (Sigma) and 400 UmL−1
superoxide dismutase from bovine erythrocytes (Sigma) to minimise oxidative
damage. After ~5 min at 4 °C, 15 μL of the mixture was removed as a control,
and the remaining sample added to a glass vial containing sufficient piericidin
A (dried from an ethanolic stock solution to avoid addition of solvent) to give
200 μM. Then, each sample was applied to a Superose 6 Increase 5/150 column
(GE Healthcare) and eluted in 20 mM Tris-Cl (pH 7.14 at 20 °C), 150 mM NaCl
and 0.05% DDM4. The concentration of the peak piericidin-bound fraction (at
∼1.65 mL) was estimated as 4.1 mg mL−1 using a nanodrop UV–vis
spectrophotometer (ε280= 0.2 (mg mL−1)−1). It was found to be 88.7 ± 3.4%
inhibited by comparing initial rates of catalysis by the control and inhibited
samples in 20 mM Tris-HCl (pH 7.5 at 20 °C), 0.012% asolectin and 0.012%
CHAPS, using 5 μM DQ and 10 μg mL−1 AOX, with catalysis initiated by 200 μM
NADH and monitored at 340–380 nm (ε= 4.81 mM−1 cm−1). The low DQ
concentration was used to minimise competition with the piericidin. The specific
activity of the control (measured in 0.075% asolectin, 0.075% CHAPS and 100 μM
DQ) was 11.3 ± 0.6 μmol min−1 mg−1.
CryoEM grid preparation, data acquisition, and processing. UltrAuFoil® gold
grids (0.6/1, Quantifoil Micro Tools GmbH) were glow discharged (20 mA, 60 s),
incubated in a solution of 5 mM 11-mercaptoundecyl hexaethyleneglycol (SPT-
0011P6, SensoPath Technologies) in ethanol for 2 days in an anaerobic glovebox,
then washed with ethanol and air-dried just before use11. Using an FEI Vitrobot
Mark IV, 2.5 μL of complex I solution (3–5 mgmL−1) was applied to each grid at 4
°C in 100% relative humidity and blotted for 10–12 s at force setting –10, before the
grid was frozen by plunging it into liquid ethane. Grids for the piericidin-K2
dataset were imaged using a Gatan K2 detector and GIF Quantum energy filter
mounted on an FEI 300 keV Titan Krios microscope with a 100 μm objective
aperture and EPU-1.9 software at the UK National Electron Bio-Imaging Centre
(eBIC) at Diamond. The energy filter was operated in zero-energy-loss mode with a
slit width of 20 eV. Data were imaged at 1.05 Å pixel−1 (magnification 47,600×)
with a defocus range −2.2 to −3.4 μm and the autofocus routine run every 10 μm.
The dose rate was 5 electrons Å−2 s−1 with 10 s exposures captured in 25 frames
(total dose ~50 electrons Å−2). Grids for the piericidin-FIII dataset were imaged
using a Falcon III detector on an FEI 300 keV Titan Krios microscope with a 100
μm objective aperture and EPU-1.9 at the Astbury Centre for Structural Molecular
Biology, University of Leeds. The detector was operated in counting mode and data
were imaged at 1.06 Å pixel−1 (magnification 130,000×) with a defocus range −2.2
to −3.8 μm and the autofocus routine run every 10 μm. The dose rate was 0.64
electrons Å−2 s−1 with 71.5 s exposures captured in 40 frames (total dose 46
electrons Å−2).
All data were processed first using RELION-2.1-patchb147. First, beam-induced
movement was corrected for using MotionCor248, both with and without dose
weighting. CFT estimations were taken from nondose weighted micrographs using
GCTF-1.0649. Following autopicking and manual curation 60,107 particles were
extracted from 1200 K2 micrographs and 76,802 particles from 1454 Falcon III
micrographs. The particles were extracted from dose-weighted micrographs and CTF
corrected with an amplitude contrast of 0.1 for 2D classification, then CTF parameters
were re-estimated with an amplitude contrast of 0.08 thereafter. For the K2 dataset,
frames 1–12 were used for movie refinement (total dose 24 electrons Å−2) with a
running average window of 3, and polished to account for movement and radiation
damage using a single frame average for B-factor estimation. For the Falcon III
dataset, frames 122 were used with a total dose of 25 electrons Å−2, with a running
average window of 5 and polished using a 3-frame average for B-factor estimation.
The particles were then subjected to 3D classification into five classes with angular
sampling gradually incremented to 0.9°. For the K2 dataset, the major class containing
27,193 particles was taken forward to the final 3D refinement with solvent flattened
FSC curves. For the Falcon III dataset, two classes containing similar numbers of
particles at the same resolution were selected and combined in a single class of 36,759
particles for refinement. Subsequently, both datasets plus the previously-described
data for the active state of mouse complex I4 were re-analysed using RELION-3.0.
Beam-induced movement was re-analysed using the in-built version of MotionCor2
and the final particles were re-extracted in RELION-3.0, refined, and subjected to
Bayesian polishing and CTF refinement, including beam tilt and per-particle
astigmatism correction, before the final refinement with solvent flattened FSC
curves50. 12 frames were used for both K2 datasets, and all 40 frames for the Falcon
III dataset. All three maps were post-processed using default parameters using a mask
created with the mask creation tool in RELION, and a soft edge of 5, starting from a
Molmap command on a pdb model of the piericidin-inhibited enzyme in UCSF
Chimera-1.13.151. Map resolution estimates are based on the FSC= 0.143 criterion52.
Pixel sizes were adjusted to three decimal places; the scaling was determined by using
the Chimera “fit in map” command to maximise the correlation between the maps.
Example micrographs and 2D classes for all three datasets are shown in
Supplementary Fig 2 and local resolution estimates, particle orientation distributions
and FSC curves are shown in Supplementary Fig 3.
Model building, refinement, and validation. The model for the active mouse
(6G2J.PDB4) was fitted into the piericidin-K2 map using Chimera51, then refined
against the RELION-sharpened piericidin-K2 map by cycles of manual adjustment
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in Coot-0.8.9.1/0.9-pre53 and real-space refinement in Phenix-1.13-2998 or 1.16-
354954 with secondary structure restraints. Model building in poorly resolved areas
was aided by the unsharpened map and a blurred map. The piericidin A molecule
was imported from ChemSpider and restraints generated using AceDRG55. The
piericidin-K2 final model was then fitted into the active map using Chimera; the
piericidin was removed, the B-factors reset to 20, and the model refinement and
inspection carried out as above. Model-to-map FSC curves were generated by
simulating a map from the model at Nyquist frequency created with Molmap in
Chimera51. The created map was compared to a masked unfiltered, unsharpened
experimental map from RELION using the Xmipp tool in SCIPION-1.256. Final
model statistics were produced by Phenix-1.16-3549, MolProbity-4.457 (Supple-
mentary Table 1) and EMRinger58 (scores 3.77 for piericidin K2, 3.33 for active,
and 3.06 for the piericidin-K2 model in the piericidin-FIII map). Finally, each
model was checked for overfitting by first “shaking” it using Phenix simple
dynamics and resetting its B-factors to 20, then refining it against an unsharpened
half map filtered to the FSC= 0.143 resolution of the combined map, and com-
paring the model-to-map FSC curves against each unfiltered, masked half map.
Local resolution maps were produced in RELION-3.0 and visualised in Chimera.
Small changes to the model (Supplementary Table 1), relative to PDB ID: 6G2J
include: identification of a cis-proline, present in high resolution structures of the
homologous NiFe hydrogenase enzymes such as from Ralstonia eutropha (PDB ID:
4IUC)59, next to cluster N2 (NDUFS7 Pro160); replacement of the ADP bound to
NDUFA10 with ATP, with π-stacking between its adenine ring and nearby Phe134;
replacement of two PE molecules (M505 and M506 from 6G2J) by a single car-
diolipin (N501); improvements to poorly resolved areas such as the N-terminal
loops of subunits NDUFS2, NDUFA13, NDUFB7, and NDUFB10.
EPR measurements. Piericidin-bound bovine complex I was prepared by com-
bining the standard method for bovine complex I8,32 with the method for the
piericidin-bound mouse enzyme. Starting from 70mg membrane protein, the
sample was concentrated to 500 μL after ion-exchange chromatography. Two
hundred and fifty microliter (the nonturnover control) were applied immediately
to a 10/300 Superose 6 Increase column; the other 250 μL were divided in two and
treated like the mouse preparation to generate a 125 μL “turnover control” without
piericidin and a 125 μL sample inhibited with 320 μM piericidin. Both were applied
to a 5/150 Superose 6 increase column. All three resulting samples were con-
centrated, and ~ 8 μL per sample was placed in a 1.6 mmO.D. Suprasil quartz EPR
tube and frozen immediately. Their concentrations were 18 (nonturnover), 13.9
(turnover) and 10 (piericidin-containing) mg mL−1 and the maximal activity of the
nonturnover control was 16.4 ± 0.2 μmol min−1 mg−1. All the procedures descri-
bed were carried out in air (not anaerobically), to match the conditions of cryo-EM
grid preparation. EPR measurements were performed using an X/Q-band Bruker
Elexsys E580 spectrometer (Bruker BioSpin GmbH, Germany) equipped with a
closed cycle cryostat (Cryogenic Ltd. UK) and Bruker Xepr software. Measure-
ments were carried out at X-band (9.5 GHz) using a split-ring resonator module
with 2 mm sample access (ER 4118X-MS2)60. The temperature and magnetic field
were calibrated with an external Cernox thermometer and a Bruker strong pitch
sample (g= 2.0028) at room temperature. Acquisition times for spectra were
approximately 12.5 min per sample. All spectra have been baseline-subtracted
using an oxidised complex I sample.
Preparation and characterisation of proteoliposomes. Proteoliposomes were
produced using complex I from bovine heart and recombinant Trypanosoma brucei
brucei AOX8,32. Briefly, liposomes were formed from 8mg phosphatidylcholine, 1
mg phosphatidylethanolamine and 1 mg cardiolipin (bovine heart extracts from
Avanti Polar Lipids) together with varying amounts of Q10 (Sigma-Aldrich) in 10
mM Tris-SO4 (pH 7.5 at 4 °C) and 50 mM KCl. Following extrusion with a 0.1 µm
track etched membrane, they were partially solubilized with 1.5% octyl-glucoside
(Anatrace). AOX (0.2 mg) and then complex I (0.2 mg) were added for recon-
stitution. Aliquots of Biobeads (Bio-Rad) were added hourly over 4 h to remove the
detergent then the proteoliposomes collected by centrifugation, resuspended, and
flash frozen for storage at –80 °C. Total protein concentrations were quantified
using the amido black assay, and the amount and orientation of complex I using
the NADH:APAD+ activity assay8,32. Total phospholipid contents were deter-
mined as follows8,32. Hundred microliter of sample or KH2PO4 as standard, 50 μL
of methanol and 30 μL of 390 mM Mg(NO3)2 in ethanol were heated in boiling
tubes over a roaring blue flame until no further brown fumes were formed to leave
a white residue. After 5 min, 0.3 mL of 500 mM HCl was added, and the tubes were
lightly stoppered, incubated at 99 °C for 15 min, cooled, and then 0.7 mL of an
aqueous solution of 114 mM ascorbic acid, 2.72 mM (NH4)6Mo7O24 and 400 mM
H2SO4 was added, and the tubes incubated at 37 °C for 1 h. The absorbances were
measured at 820 nm. One milligram of phospholipid was assumed to occupy a
volume of 1 μL8,32. Q10 was quantified by HPLC. Five to ten microliter of sample
were solubilised in 190 µL HPLC grade ethanol, then 50 µL loaded onto a Nucleosil
100-5C18 (Hichrom) column maintained at 30 °C on an Agilent 1100 series HPLC
system. The mobile phase (run at 800 µL min−1) contained 70% ethanol, 30%
methanol, 0.7% NaClO4, 0.07% HClO48 with elution monitored using a Dionex
Ultimate 3000 RS electrochemical detector. A conditioning electrode (6020RS omni
Coulometric cell) placed before the sample injector was set to +1000 mV and the
dual electrodes of the detecting Coulometric cell (6011RS Ultra Analytical cell)
were set to –500 and +450 mV. The ubiquinone content was calculated from its
+450 mV-peak area, by comparison to a set of standards. Ubiquinone con-
centrations are expressed as nmol of Q10 per mg of phospholipids, which equates to
mM concentration units.
Piericidin inhibition kinetics of complex I-AOX proteoliposomes. Catalytic
activity assays were conducted at 32 °C in 10 mM Tris-SO4 (pH 7.5 at 32 °C) and
50 mM KCl in 96-well plates using a Molecular Devices Spectramax 384 plus
platereader with Softmax Pro 5.4.42.1. Piericidin was added in ethanol and catalysis
initiated by addition of 200 µM NADH and monitored at 340 and 380 nm (ε340–380
= 4.81 mM−1 cm−1). Linear rates were measured, typically after a 100 s period of
equilibration and/or activation. Inhibitor insensitive rates (recorded using 20 nM
piericidin) were subtracted. The data are presented as mean values with standard
deviations propagated from the quantifications of enzyme, sidedness, membrane
volume, quinone content as well as the activity, which was performed in triplicate.
The data were modelled using the ordinary differential equation solver, ode15s, in
MATLAB (Mathworks, R2018a) with all the reverse rate constants (k−1, k−3, etc.)
set to 1. k4 was set to 1000 s−1 to ensure reoxidation of ubiquinol by AOX was not
rate limiting8. Rate calculations were terminated once they reached steady state
(judged as a change in enzyme-substrate complex concentration of <1 fM s−1 upon
each simulated timestep). The overall rate of NADH oxidation was calculated by
multiplying the steady-state concentration of enzyme-substrate complex with the
turnover rate (k2). Fitting was initiated repeatedly with a random set of values for
the variable parameters, and targeted on the parameter combination with the
smallest error between the calculated and measured rates; the data were modelled
simultaneously over all Q10 and piericidin concentrations. The piericidin log10P
value (4.73) was calculated in ChemSpider (http://www.chemspider.com). For most
final models, bootstrapping of the residuals (n= 1000) was conducted using the
triplicate activity measurements (rather than the means) in order to derive fitting
statistics (mean, median, and 95% confidence intervals) of model parameters. For
poorly-fitting models, uncertainties in fit parameters are the standard errors of
fitting from the nonlinear regression.
Molecular simulations. All-atom classical molecular dynamics (MD) simulations
(see Supplementary Table 4) were performed using our resolved piericidin-K2
structure of mouse complex I. Chains A, B, C, D (residues 34–430), H, I, J, K, P, a,
b, e, r, W, X (residues 1–150), and Z were embedded in a POPC membrane and
solvated with TIP3P water and 100 mM NaCl. The entire system comprised
~396,000 atoms. Force field parameters for the cofactors were derived from DFT
models61. Parameters for piericidin were estimated initially using CGenFF62, and
refined at B3LYP-D3/def2-TZVP level63. Protonation states of key titratable amino
acids were determined by Poisson–Boltzmann electrostatic (PBE) calculations64
and long-range electrostatics treated by the Particle Mesh Ewald method. All
simulations were performed at 1 atm, 310 K, with a 2 fs integration timestep. After
initial minimisation, the system was heated up to the final temperature using a set
of harmonic restraints (2 kcal mol−1 Å−2) on the entire protein structure and
cofactors (0.5 ns), then in a second step restrains were applied only to the backbone
atoms (1 ns). Simulations were performed using NAMD 2.9/2.1365 and analysed
using VMD66.
The initial structure of piericidin near Tyr108 was based on the cryoEM model
(simulation A1–A3, A5–A6), or docked in de novo (simulation A4) using the
cryoEM density. The structure of the piericidin in the lower part of the cavity
(simulation A1, A2, and A4) was based on the local quinone-binding substrates
described previously, that correspond to local binding minima identified in
simulations of T. thermophilus complex I34. The second binding site was also
probed by molecular docking calculations. Although some docked models could be
identified with qualitative resemblance to the MD poses, the best scoring models
were qualitatively incorrect, and the approach was therefore not employed for
further exploration of the site. Water clustering analysis was performed on the last
40 ns (2000 frames) of simulation A1 using the WATCLUST method67, with
standard clustering values, and a 10% threshold for cluster recognition. Water
molecules ∼3 Å from residues NDUFS2 Asp107, Thr156, Lys371, Asp422, and
Val424 were considered in the clustering analysis.
All setups were optimised using the molecular dynamics flexible fitting (MDFF)
procedure27. MDFF simulations of piericidin were carried out using the inner core
of the quinone-binding cavity (subunits ND1, NDUFS2, and NDUFS7), and
imposing secondary structure restraints on the backbone atoms of the protein, plus
a distance restraint of 1.7 Å between the Tyr108 hydroxyl and the piericidin 1′
carbonyl. After initial minimisation, the system was equilibrated at 310 K for 1 ns,
followed by minimisation with high restraints on the experimental density.
Simulations based on the cryoEM model were subject only to the latter. Energy
decomposition analyses comprised all residues within 5 Å, and included
interactions with protein backbone atoms.
Coarse-grained molecular dynamics (CGMD) simulations (see Supplementary
Table 4) were performed using the MARTINI 2.2 force field68. In total, 10 × 10 µs
simulations using a 20 fs timestep, a semi-isotropic Parrinello–Rahman barostat
with a coupling constant of τp= 12.0 ps, and a compressibility of χ= 3.0 × 10−4
bar−1 were carried out. The simulation temperature was set to T= 310 K with a
thermostat coupling constant of τt= 1.0 ps. Nonbonded interactions were treated
using a cutoff distance of 11 Å and ε= 15. Piericidin was placed in different
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-18950-3 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:5261 | https://doi.org/10.1038/s41467-020-18950-3 | www.nature.com/naturecommunications 9
starting positions across the quinone channel. The CGMD simulations performed
using Gromacs 2016.369.
To obtain a parameter-free estimation of binding poses in the active site, QM/
MM MD simulations (see Supplementary Table 4) were performed with the
piericidin, Tyr108, His59, Thr156, and Asp160 in the QM region treated at the
B3LYP-D3/def2-SVP level of theory63. Protein residues within 10 Å of the
piericidin were allowed to move during the dynamics. The total QM/MM system
was trimmed to include 9100 atoms. The classical region was modelled at the
CHARMM36 level of theory in combination with in-house DFT parameters for the
cofactors (see above). All QM/MM simulations were performed using the
CHARMM c38b, TURBOMOLE 6.6–7.3 and the CHARMM/TURBOMOLE
interface70.
A complete list of all simulations performed are shown in Supplementary
Table 4.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Data accession codes: EMD-11424, PDB ID: 6ZTQ (piericidin-bound structure), EMD-
11425 (piericidin-bound map from the FIII detector), EMD-11377, PDB ID: 6ZR2 (active
state structure). Other data supporting the findings of this manuscript are available from
the corresponding authors upon reasonable request.
Code availability
The Matlab algorithms used for kinetics modelling are available from the corresponding
authors upon request.
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